Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Momentum forward

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 24, 2022 7:42pm

193 Views

Post# 35126681

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Momentum forward

Why file for any further IP when ONCY's manufacturing IP is valid and extendable to 2034 and the FDA's provision on innovative biological products provides 12 years marketing exclusivity on novel biologics from the date the product is granted marketing approval. Should ONCY's acquirer decide on further patent protection the acquirer will be able to file and be assigned the relative patent rights without ONCY's or Matt Coffey's assignments.

<< Previous

Bullboard Posts

Next >>

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!